Maleki-Yazdi , M R , Molimard , M , Keininger , D L , Gruenberger , J-B , Carrasco , J , Pitotti , C , Sauvage , E , Chehab , S & Price , D B 2016 , ' Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal ' , Applied Health Economics and Health Policy , vol. 14 , no. 5 , pp. 579-594 . https://doi.org/10.1007/s40258-016-0256-z